Abstract
Recently, the orphan receptor G protein-coupled receptor 55 (GPR55) has been proposed as a potential cannabinoid receptor, although controversy remains on its physiological roles. Current evidence suggests a role for GPR55 as a receptor for the lysophospholipid lysophosphatidylinositol (LPI). In this study, we show that GPR55 is expressed in several prostate and ovarian cancer cell lines, both at the mRNA and at the protein level, and that it has a critical role in regulating proliferation and anchorage-independent growth. We further show that GPR55 mediates the effects of LPI in prostate and ovarian cancer cells. Indeed we demonstrate that LPI is able to induce calcium mobilization and activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in these cells and that both pharmacological blockade of GPR55 and its downregulation using specific small interfering RNA strongly inhibits these processes. We further identify an autocrine loop by which LPI is synthesized by cytosolic phospholipase A2, pumped out of the cell by the ATP-binding cassette transporter ABCC1/MRP1, and is then able to initialize cascades downstream of GPR55. All together, these data demonstrate a role of LPI and its receptor GPR55 in cancer cells in activating an autocrine loop that regulates cell proliferation. These findings may have important implications for LPI as a novel cancer biomarker and for its receptor GPR55 as a potential therapeutic target.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D et al. (1999). Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551–2556.
Falasca M, Corda D . (1994). Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur J Biochem 221: 383–389.
Falasca M, Iurisci C, Carvelli A, Sacchetti A, Corda D . (1998). Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 16: 2357–2365.
Falasca M, Silletta MG, Carvelli A, Di Francesco AL, Fusco A, Ramakrishna V et al. (1995). Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 10: 2113–2124.
Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ et al. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762–771.
Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ . (2009). The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183–193.
Hoffmann U, Kroemer HK . (2004). The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36: 669–701.
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS et al. (2009). Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284: 29817–29827.
Kreitzer FR, Stella N . (2009). The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 122: 83–96.
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K . (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105: 2699–2704.
Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S . (2006). Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 103: 16394–16399.
Monet M, Gkika D, Lehen′kyi V, Pourtier A, Vanden Abeele F, Bidaux G et al. (2009). Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 1793: 528–539.
Nevalainen T, Irving AJ . (2010). GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem 10: 799–813.
Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T . (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671–678.
Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T . (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928–934.
Patel MI, Singh J, Niknami M, Kurek C, Yao M, Lu S et al. (2008). Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res 14: 8070–8079.
Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC et al. (2004). Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 279: 11320–11326.
Ross RA . (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156–163.
Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092–1101.
Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH et al. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64: 193–198.
Sharir H, Abood ME . (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301–313.
Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J et al. (2005). Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326: 744–751.
Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP et al. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225–236.
Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN . (1998). The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4: 1393–1403.
Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN . (2000). Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105: 1261–1267.
Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys Jr EC, LaPolla JP et al. (2004). Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1185–1191.
Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M et al. (2008). Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121: 1704–1717.
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ et al. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511–16516.
Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y . (2000). Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 905: 242–259.
Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J et al. (2001). Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 290: 302–313.
Yin H, Chu A, Li W, Wang B, Shelton F, Otero F et al. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284: 12328–12338.
Acknowledgements
We thank Prof D Baker (Queen Mary University of London), Prof WH Moolenaar (The Netherlands Cancer Institute), Dr N Divecha (The Paterson Institute for Cancer Research, Manchester) and Dr R Sabatini (LPath Inc) for critical reading of the paper. We also thank the National Institute of Drug Abuse, Bethesda, MD, USA for providing SR141716A. RP was supported by the British Heart Foundation (grant PG/06/022/204348 to MF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Piñeiro, R., Maffucci, T. & Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142–152 (2011). https://doi.org/10.1038/onc.2010.417
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.417
Keywords
This article is cited by
-
Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning
Cell Communication and Signaling (2021)
-
Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
Histochemistry and Cell Biology (2021)
-
Immune-related genes in tumor-specific CD4+ and CD8+ T cells in colon cancer
BMC Cancer (2020)
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function (2020)
-
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer
Journal of Experimental & Clinical Cancer Research (2019)